2 hours Ago By Defense World Staff
Unique Wealth LLC raised its position in shares of Stryker Co. ( NYSE:SYK – Free Report ) by 16.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission.
The firm owned 6,147 shares of the medical technology company’s stock after buying an additional 848 shares during the period. Unique Wealth LLC’s holdings in Stryker were worth $2,221,000 at the end of the most recent reporting period. A number of other large investors have also added to or reduced their stakes in SYK.
Czech National Bank increased its stake in shares of Stryker by 8.1% during the third quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock valued at $25,231,000 after buying an additional 5,235 shares during the period.
Massmutual Trust Co. FSB ADV boosted its holdings in Stryker by 4.5% in the third quarter.
Massmutual Trust Co. FSB ADV now owns 69,157 shares of the medical technology company’s stock valued at $24,984,000 after acquiring an additional 2,952 shares in the last quarter. American National Bank & Trust increased its position in Stryker by 14.
3% during the 3rd quarter. American National Bank & Trust now owns 34,200 shares of the medical technology company’s stock valued at $12,355,000 after purchasing an additional 4,281 shares during the period. Appleton Partners Inc.
MA raised its holdings in Stryker by 0.7% in the 3rd quarter. Appleton Partners Inc.
MA now owns 27,822 shares of the medical technology company’s stock worth $10,051,000 after purchasing an additional 182 shares in the last quarter. Finally, Centaurus Financial Inc. lifted its position in shares of Stryker by 11.
3% in the 2nd quarter. Centaurus Financial Inc. now owns 1,047 shares of the medical technology company’s stock worth $356,000 after purchasing an additional 106 shares during the period.
Institutional investors own 77.09% of the company’s stock. Wall Street Analysts Forecast Growth SYK has been the topic of several research analyst reports.
BTIG Research boosted their price target on shares of Stryker from $360.00 to $374.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th.
Royal Bank of Canada restated an “outperform” rating and issued a $386.00 target price on shares of Stryker in a research note on Wednesday, July 31st. Barclays lifted their price target on Stryker from $374.
00 to $402.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. UBS Group raised their price objective on Stryker from $351.
00 to $366.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, Morgan Stanley upped their target price on shares of Stryker from $345.
00 to $350.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock.
According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $379.37. Stryker Trading Down 1.
0 % Shares of SYK stock opened at $351.61 on Friday. The company has a current ratio of 1.
68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51.
Stryker Co. has a 12-month low of $249.98 and a 12-month high of $374.
63. The stock has a market capitalization of $133.99 billion, a P/E ratio of 40.
14, a P/E/G ratio of 2.74 and a beta of 0.91.
The firm’s 50 day moving average is $349.38 and its 200 day moving average is $343.18.
Stryker ( NYSE:SYK – Get Free Report ) last released its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.
79 by $0.02. Stryker had a return on equity of 22.
89% and a net margin of 16.12%. The firm had revenue of $5.
42 billion for the quarter, compared to the consensus estimate of $5.40 billion. During the same period last year, the business posted $2.
54 EPS. The company’s revenue for the quarter was up 8.5% on a year-over-year basis.
Research analysts expect that Stryker Co. will post 12 earnings per share for the current year. Stryker Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st.
Shareholders of record on Monday, September 30th will be given a $0.80 dividend. The ex-dividend date is Monday, September 30th.
This represents a $3.20 annualized dividend and a yield of 0.91%.
Stryker’s payout ratio is presently 36.53%. Insider Activity In related news, insider Viju Menon sold 600 shares of Stryker stock in a transaction on Tuesday, August 27th.
The stock was sold at an average price of $355.00, for a total transaction of $213,000.00.
Following the transaction, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . In other news, Director Ronda E.
Stryker sold 190,000 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total value of $61,457,400.
00. Following the completion of the sale, the director now directly owns 3,316,608 shares of the company’s stock, valued at $1,072,790,023.68.
The sale was disclosed in a filing with the SEC, which is accessible through the SEC website . Also, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.
00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495.
The disclosure for this sale can be found here . Insiders sold a total of 220,068 shares of company stock valued at $71,811,372 in the last 90 days. Company insiders own 5.
90% of the company’s stock. Stryker Company Profile ( Free Report ) Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine.
The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Further Reading Five stocks we like better than Stryker What is Short Interest? How to Use It When Is the Best Time to Invest in Mutual Funds? What is a Death Cross in Stocks? Is NVIDIA Stock in a Correction or Consolidation? Should You Add These Warren Buffett Stocks to Your Portfolio? 3 Oversold Stocks with Big RSI Rebound Potential Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co.
( NYSE:SYK – Free Report ). Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter .
.
